A Phase 2, multicenter, Open-Label, Long-Term Safety Study of LP352 in Subjects with Developmental and Epileptic Encephalopathy who Completed Study LP352-201 and are Candidates for Continuous Treatmen

Activity Type
Clinical Trial
Date
Dollar Amount
*
Grant Type
Contract
Principal Investigator
David Labiner
Sponsor
Longboard Pharmaceuticals, Inc.
Unit
Neurology